Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry

Jung Sun Kim, Byoung Ho Lee, Young Guk Ko, Donghoon Choi, Yangsoo Jang, Pil Ki Min, Young Won Yoon, Bum Kee Hong, Hyuck Moon Kwon, Min Soo Ahn, Seung Hwan Lee, Jung Han Yoon, Byoung Kwon Lee, Byung Ok Kim, Byeong Kuk Kim, Sung Jin Oh, Dong Woon Jeon, Joo Young Yang, Jung Rae Cho, Jae Hun JungSeung Ki Ryu, K. Kwon, S. H. Park, Y. S. Byun, C. W. Ko

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM.

Original languageEnglish
Pages (from-to)601-607
Number of pages7
JournalCatheterization and Cardiovascular Interventions
Volume72
Issue number5
DOIs
Publication statusPublished - 2008 Nov 1

Fingerprint

Sirolimus
Paclitaxel
Angioplasty
Stents
Registries
Thrombosis
Propensity Score
Diabetes Mellitus

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Jung Sun ; Lee, Byoung Ho ; Ko, Young Guk ; Choi, Donghoon ; Jang, Yangsoo ; Min, Pil Ki ; Yoon, Young Won ; Hong, Bum Kee ; Kwon, Hyuck Moon ; Ahn, Min Soo ; Lee, Seung Hwan ; Yoon, Jung Han ; Lee, Byoung Kwon ; Kim, Byung Ok ; Kim, Byeong Kuk ; Oh, Sung Jin ; Jeon, Dong Woon ; Yang, Joo Young ; Cho, Jung Rae ; Jung, Jae Hun ; Ryu, Seung Ki ; Kwon, K. ; Park, S. H. ; Byun, Y. S. ; Ko, C. W. / Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients : The Korean multicenter angioplasty team (KOMATE) registry. In: Catheterization and Cardiovascular Interventions. 2008 ; Vol. 72, No. 5. pp. 601-607.
@article{de190f31806b42a48b33de7142c25f3e,
title = "Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry",
abstract = "Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1{\%}) in SES vs. 29 (14.1{\%}) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8{\%}) in SES vs. 7 (3.4{\%}) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM.",
author = "Kim, {Jung Sun} and Lee, {Byoung Ho} and Ko, {Young Guk} and Donghoon Choi and Yangsoo Jang and Min, {Pil Ki} and Yoon, {Young Won} and Hong, {Bum Kee} and Kwon, {Hyuck Moon} and Ahn, {Min Soo} and Lee, {Seung Hwan} and Yoon, {Jung Han} and Lee, {Byoung Kwon} and Kim, {Byung Ok} and Kim, {Byeong Kuk} and Oh, {Sung Jin} and Jeon, {Dong Woon} and Yang, {Joo Young} and Cho, {Jung Rae} and Jung, {Jae Hun} and Ryu, {Seung Ki} and K. Kwon and Park, {S. H.} and Byun, {Y. S.} and Ko, {C. W.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1002/ccd.21700",
language = "English",
volume = "72",
pages = "601--607",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Kim, JS, Lee, BH, Ko, YG, Choi, D, Jang, Y, Min, PK, Yoon, YW, Hong, BK, Kwon, HM, Ahn, MS, Lee, SH, Yoon, JH, Lee, BK, Kim, BO, Kim, BK, Oh, SJ, Jeon, DW, Yang, JY, Cho, JR, Jung, JH, Ryu, SK, Kwon, K, Park, SH, Byun, YS & Ko, CW 2008, 'Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients: The Korean multicenter angioplasty team (KOMATE) registry', Catheterization and Cardiovascular Interventions, vol. 72, no. 5, pp. 601-607. https://doi.org/10.1002/ccd.21700

Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients : The Korean multicenter angioplasty team (KOMATE) registry. / Kim, Jung Sun; Lee, Byoung Ho; Ko, Young Guk; Choi, Donghoon; Jang, Yangsoo; Min, Pil Ki; Yoon, Young Won; Hong, Bum Kee; Kwon, Hyuck Moon; Ahn, Min Soo; Lee, Seung Hwan; Yoon, Jung Han; Lee, Byoung Kwon; Kim, Byung Ok; Kim, Byeong Kuk; Oh, Sung Jin; Jeon, Dong Woon; Yang, Joo Young; Cho, Jung Rae; Jung, Jae Hun; Ryu, Seung Ki; Kwon, K.; Park, S. H.; Byun, Y. S.; Ko, C. W.

In: Catheterization and Cardiovascular Interventions, Vol. 72, No. 5, 01.11.2008, p. 601-607.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of sirolimus-eluting stent and paclitaxel-eluting stent for long-term cardiac adverse events in diabetic patients

T2 - The Korean multicenter angioplasty team (KOMATE) registry

AU - Kim, Jung Sun

AU - Lee, Byoung Ho

AU - Ko, Young Guk

AU - Choi, Donghoon

AU - Jang, Yangsoo

AU - Min, Pil Ki

AU - Yoon, Young Won

AU - Hong, Bum Kee

AU - Kwon, Hyuck Moon

AU - Ahn, Min Soo

AU - Lee, Seung Hwan

AU - Yoon, Jung Han

AU - Lee, Byoung Kwon

AU - Kim, Byung Ok

AU - Kim, Byeong Kuk

AU - Oh, Sung Jin

AU - Jeon, Dong Woon

AU - Yang, Joo Young

AU - Cho, Jung Rae

AU - Jung, Jae Hun

AU - Ryu, Seung Ki

AU - Kwon, K.

AU - Park, S. H.

AU - Byun, Y. S.

AU - Ko, C. W.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM.

AB - Background: There is some controversy on long-term cardiac outcomes between sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in diabetes mellitus (DM). We compared cardiac adverse events after SES and PES implantation in patients with DM over a period of 3 year. Methods: A total of 634 patients with DM treated with SES (n 5 428) or PES (n 5 206) were consecutively enrolled in the KOMATE registry from 2003 to 2004. We assessed major adverse cardiac events (MACEs, cardiovascular death, non-fatal myocardial infarction, ischemia driven target vessel revascularization) and stent thrombosis (ST) according to the definitions set by the Academic Research Consortium. Results: Propensity score (PS) analysis was performed to adjust different baseline characteristics. The mean follow-up duration was 38 ± 8 month (at least 36 month and up to 53 month). The 3-year MACE rate did not show a significant difference between the two groups [52 (12.1%) in SES vs. 29 (14.1%) in PES, P = 0.496]. The definite and probable ST at 3 year were similar in both SES and PES [12 (2.8%) in SES vs. 7 (3.4%) in PES, P = 0.681]. There were no differences in hazard ratio for MACE and ST between two stents [MACE, crude: 0.844 (0.536-1.330) and adjusted for PS: 0.858 (0.530-1.389); ST, crude: 0.820 (0.323-2.083) and adjusted for PS: 0.960 (0.357-2.587)]. Conclusions: The present study demonstrated that long-tem cardiac outcomes including ST were not significantly different between SES and PES in patients with DM.

UR - http://www.scopus.com/inward/record.url?scp=58749099139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749099139&partnerID=8YFLogxK

U2 - 10.1002/ccd.21700

DO - 10.1002/ccd.21700

M3 - Article

C2 - 18942123

AN - SCOPUS:58749099139

VL - 72

SP - 601

EP - 607

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

IS - 5

ER -